The Juvenile Diabetes Research Foundation (JDRF) is teaming up with Jonson & Johnson’s Animas Corporation to develop an artificial pancreas by integrating and automating existing technologies, and developing control algorithms to make everything work smoothly together. The project has a three year development time frame and another year to seek FDA clearance.
Project goals from the press release:
The first-generation system would be partially automated, utilizing an insulin pump connected wirelessly with a continuous glucose monitor (CGM). The CGM continuously reads glucose levels through a sensor with a hair-thin sensor wire inserted just below the skin, typically on the abdomen. The sensor would transmit those readings to the insulin pump, which delivers insulin through a small tube or patch on the body. The pump would house a sophisticated computer program that will address safety concerns during the day and night, by helping prevent hypoglycemia and extreme hyperglycemia. It would slow or stop insulin delivery if it detected blood sugar was going too low and would increase insulin delivery if blood sugar was too high. For example, the system would automatically discontinue insulin delivery to help prevent hypoglycemia, and then automatically resume insulin delivery based on a specific time interval (i.e., 2 hours) and/or glucose concentration. It will also automatically increase insulin delivery to reduce the amount of time spent in the hyperglycemic range and return to a pre-set basal rate once glucose concentrations have returned to acceptable levels.
In this early version of an automated diabetes management system, the patient would still need to manually instruct the pump to deliver insulin at times, (i.e. around meals). But this “hypoglycemia-hyperglycemia minimizer” system would represent a significant step forward in diabetes management, and could provide immediate benefits in terms of blood sugar control, by minimizing dangerous highs and lows.
Amy Tenderich over at DiabetesMine spoke with some folks from JDRF to get a better idea of what the $8 million investment is all about. She also received commitment from JDRF to answer any questions readers would like to ask directly on her website.
Link at DiabetesMine: JDRF Joins with Animas & DexCom to Build “First-Generation” Artificial Pancreas…
Press release: JDRF Forms Partnership With Animas to Develop First-Generation Automated System for Managing Type 1 Diabetes…
Link: Artificial Pancreas Project….
